Free Trial

Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Consensus Recommendation of "Buy" by Brokerages

Jasper Therapeutics logo with Medical background

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) have received an average recommendation of "Buy" from the ten brokerages that are currently covering the stock, MarketBeat.com reports. Ten equities research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have covered the stock in the last year is $73.38.

A number of analysts have recently issued reports on JSPR shares. HC Wainwright reiterated a "buy" rating and set a $65.00 target price on shares of Jasper Therapeutics in a report on Thursday, October 24th. Royal Bank of Canada decreased their price objective on shares of Jasper Therapeutics from $70.00 to $68.00 and set an "outperform" rating for the company in a research note on Wednesday, August 14th. Cantor Fitzgerald reissued an "overweight" rating on shares of Jasper Therapeutics in a research note on Monday, September 9th. JMP Securities reaffirmed a "market outperform" rating and set a $70.00 price target on shares of Jasper Therapeutics in a research report on Tuesday, October 15th. Finally, Evercore ISI reiterated an "outperform" rating and issued a $65.00 price target on shares of Jasper Therapeutics in a report on Monday, August 26th.

Check Out Our Latest Stock Report on Jasper Therapeutics

Jasper Therapeutics Trading Up 4.4 %

NASDAQ:JSPR traded up $0.95 on Friday, hitting $22.48. 189,379 shares of the stock were exchanged, compared to its average volume of 205,271. The stock has a fifty day moving average of $20.54 and a 200-day moving average of $20.92. The stock has a market cap of $337.20 million, a PE ratio of -4.74 and a beta of 2.18. Jasper Therapeutics has a fifty-two week low of $4.00 and a fifty-two week high of $31.01.

Institutional Trading of Jasper Therapeutics

Large investors have recently modified their holdings of the business. Samsara BioCapital LLC grew its position in shares of Jasper Therapeutics by 11.4% during the third quarter. Samsara BioCapital LLC now owns 584,642 shares of the company's stock worth $10,997,000 after buying an additional 59,642 shares in the last quarter. Braidwell LP bought a new position in Jasper Therapeutics during the 3rd quarter valued at $9,091,000. Ally Bridge Group NY LLC grew its holdings in Jasper Therapeutics by 82.7% during the 3rd quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company's stock worth $7,514,000 after acquiring an additional 180,852 shares in the last quarter. State Street Corp raised its stake in shares of Jasper Therapeutics by 12.3% in the 3rd quarter. State Street Corp now owns 214,883 shares of the company's stock valued at $4,042,000 after purchasing an additional 23,564 shares in the last quarter. Finally, Fernwood Investment Management LLC raised its stake in shares of Jasper Therapeutics by 6.9% in the 3rd quarter. Fernwood Investment Management LLC now owns 52,897 shares of the company's stock valued at $995,000 after purchasing an additional 3,427 shares in the last quarter. 79.85% of the stock is currently owned by institutional investors and hedge funds.

Jasper Therapeutics Company Profile

(Get Free Report

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.

Featured Articles

Analyst Recommendations for Jasper Therapeutics (NASDAQ:JSPR)

Should you invest $1,000 in Jasper Therapeutics right now?

Before you consider Jasper Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jasper Therapeutics wasn't on the list.

While Jasper Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

From Landfills to Profits: Opal Fuels CEO Shares How the Company Turns Trash into Cash
The Real Reason Tesla Stock Is Soaring – and Why Tech Expert Says It Won’t Stop
Best ETFs for 2025: Growth, Stability, and AI-Driven Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines